Zomedica Pharmaceuticals Corp. announced it has entered into a research collaboration agreement with Celsee Diagnostics, Inc. The research project defined in the agreement aims to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells, commonly referred to as CTCs, are cells that have shed from a primary tumor into neighboring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy.